Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 191

1.

Predictive and prognostic factors for gliomas.

Ducray F, Idbaih A, Wang XW, Cheneau C, Labussiere M, Sanson M.

Expert Rev Anticancer Ther. 2011 May;11(5):781-9. doi: 10.1586/era.10.202. Review.

PMID:
21554053
2.

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group.

van den Bent MJ, Dubbink HJ, Marie Y, Brandes AA, Taphoorn MJ, Wesseling P, Frenay M, Tijssen CC, Lacombe D, Idbaih A, van Marion R, Kros JM, Dinjens WN, Gorlia T, Sanson M.

Clin Cancer Res. 2010 Mar 1;16(5):1597-604. doi: 10.1158/1078-0432.CCR-09-2902.

3.

Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients.

Mukasa A, Takayanagi S, Saito K, Shibahara J, Tabei Y, Furuya K, Ide T, Narita Y, Nishikawa R, Ueki K, Saito N.

Cancer Sci. 2012 Mar;103(3):587-92. doi: 10.1111/j.1349-7006.2011.02175.x.

4.

Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas.

Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A.

Acta Neuropathol. 2010 Dec;120(6):707-18. doi: 10.1007/s00401-010-0781-z.

PMID:
21088844
5.

Metabolism of glioma and IDH1/IDH2 mutations.

Rossetto M, Ciccarino P, Boisselier B, Labussiere M, Sanson M.

Rev Neurol (Paris). 2011 Oct;167(10):699-703. doi: 10.1016/j.neurol.2011.08.002. Review.

PMID:
21885076
6.

[Guidelines for adult diffuse gliomas WHO grade II, III and IV: pathology and biology. Société franc¸aise de neuropathologie . Réseau de neuro-oncologie pathologique].

Figarella-Branger D, Labrousse F, Mohktari K; Société franc¸aise de neuropathologie.; Réseau de neuro-oncologie pathologique..

Ann Pathol. 2012 Oct;32(5):318-27. doi: 10.1016/j.annpat.2012.09.228. French.

PMID:
23141938
7.

ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma.

Reuss DE, Sahm F, Schrimpf D, Wiestler B, Capper D, Koelsche C, Schweizer L, Korshunov A, Jones DT, Hovestadt V, Mittelbronn M, Schittenhelm J, Herold-Mende C, Unterberg A, Platten M, Weller M, Wick W, Pfister SM, von Deimling A.

Acta Neuropathol. 2015 Jan;129(1):133-46. doi: 10.1007/s00401-014-1370-3.

PMID:
25427834
8.

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

Labussière M, Idbaih A, Wang XW, Marie Y, Boisselier B, Falet C, Paris S, Laffaire J, Carpentier C, Crinière E, Ducray F, El Hallani S, Mokhtari K, Hoang-Xuan K, Delattre JY, Sanson M.

Neurology. 2010 Jun 8;74(23):1886-90. doi: 10.1212/WNL.0b013e3181e1cf3a.

PMID:
20427748
9.

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

Sanson M, Marie Y, Paris S, Idbaih A, Laffaire J, Ducray F, El Hallani S, Boisselier B, Mokhtari K, Hoang-Xuan K, Delattre JY.

J Clin Oncol. 2009 Sep 1;27(25):4150-4. doi: 10.1200/JCO.2009.21.9832.

PMID:
19636000
10.

Moving toward molecular classification of diffuse gliomas in adults.

Theeler BJ, Yung WK, Fuller GN, De Groot JF.

Neurology. 2012 Oct 30;79(18):1917-26. doi: 10.1212/WNL.0b013e318271f7cb.

11.

Diagnostic and prognostic markers in gliomas.

Ducray F, El Hallani S, Idbaih A.

Curr Opin Oncol. 2009 Nov;21(6):537-42. doi: 10.1097/CCO.0b013e32833065a7. Review.

PMID:
19667985
12.

Histopathological malignant progression of grade II and III gliomas correlated with IDH1/2 mutation status.

Ohno M, Narita Y, Miyakita Y, Okita Y, Matsushita Y, Yoshida A, Fukushima S, Ichimura K, Kayama T, Shibui S.

Brain Tumor Pathol. 2012 Oct;29(4):183-91. doi: 10.1007/s10014-012-0113-1.

PMID:
22790483
13.

Genetic profile of astrocytic and oligodendroglial gliomas.

Ohgaki H, Kleihues P.

Brain Tumor Pathol. 2011 Jul;28(3):177-83. doi: 10.1007/s10014-011-0029-1. Review.

PMID:
21442241
14.

Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups.

Weller M, Weber RG, Willscher E, Riehmer V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H, Kaulich K, Steinbach JP, Hartmann C, Gramatzki D, Schramm J, Westphal M, Schackert G, Simon M, Martens T, Boström J, Hagel C, Sabel M, Krex D, Tonn JC, Wick W, Noell S, Schlegel U, Radlwimmer B, Pietsch T, Loeffler M, von Deimling A, Binder H, Reifenberger G.

Acta Neuropathol. 2015 May;129(5):679-93. doi: 10.1007/s00401-015-1409-0.

PMID:
25783747
15.

Molecular diagnostics of gliomas: the clinical perspective.

Tabatabai G, Stupp R, van den Bent MJ, Hegi ME, Tonn JC, Wick W, Weller M.

Acta Neuropathol. 2010 Nov;120(5):585-92. doi: 10.1007/s00401-010-0750-6. Review.

PMID:
20862485
16.

The hypermethylation of the O6-methylguanine-DNA methyltransferase gene promoter in gliomas--correlation with array comparative genome hybridization results and IDH1 mutation.

Tuononen K, Tynninen O, Sarhadi VK, Tyybäkinoja A, Lindlöf M, Antikainen M, Näpänkangas J, Hirvonen A, Mäenpää H, Paetau A, Knuutila S.

Genes Chromosomes Cancer. 2012 Jan;51(1):20-9. doi: 10.1002/gcc.20927.

PMID:
21922591
17.

Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial.

Dubbink HJ, Atmodimedjo PN, Kros JM, French PJ, Sanson M, Idbaih A, Wesseling P, Enting R, Spliet W, Tijssen C, Dinjens WN, Gorlia T, van den Bent MJ.

Neuro Oncol. 2016 Mar;18(3):388-400. doi: 10.1093/neuonc/nov182.

PMID:
26354927
18.

[Histological and molecular classification of gliomas].

Figarella-Branger D, Colin C, Coulibaly B, Quilichini B, Maues De Paula A, Fernandez C, Bouvier C.

Rev Neurol (Paris). 2008 Jun-Jul;164(6-7):505-15. doi: 10.1016/j.neurol.2008.03.011. Review. French.

PMID:
18565348
19.

Molecular markers in low-grade gliomas: predictive or prognostic?

Hartmann C, Hentschel B, Tatagiba M, Schramm J, Schnell O, Seidel C, Stein R, Reifenberger G, Pietsch T, von Deimling A, Loeffler M, Weller M; German Glioma Network..

Clin Cancer Res. 2011 Jul 1;17(13):4588-99. doi: 10.1158/1078-0432.CCR-10-3194.

20.

Molecular classification of low-grade diffuse gliomas.

Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, Sure U, Wrede K, Nakazato Y, Tanaka Y, Vital A, Mariani L, Stawski R, Watanabe T, De Girolami U, Kleihues P, Ohgaki H.

Am J Pathol. 2010 Dec;177(6):2708-14. doi: 10.2353/ajpath.2010.100680.

Items per page

Supplemental Content

Support Center